Results 141 to 150 of about 18,044 (238)

Advancing IBD Management: A Literature Review on the Role of Non‐Invasive Blood‐Based Biomarkers in Predicting and Assessing Pharmacodynamic Response to Treatment

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT Reliable biomarkers that enable noninvasive, longitudinal assessment of disease activity and therapeutic response remain a major unmet need in inflammatory bowel disease (IBD). While colonic biopsies are the gold standard for evaluating mucosal inflammation, their invasive nature and limited spatial and temporal resolution constrain their ...
Mohamed Hassanein, Li Xi, Rathi D. Ryan, Zhan (Harold) Ye, Nessy Tania, Yamato Sano, Joshua Varghese, Diogo Branquinho, Anna Sapone   +8 more
wiley   +1 more source

Evaluation of a Therapeutic Drug Monitoring Strategy for Adalimumab in Psoriasis: A Prospective Pharmacokinetic‐Pharmacodynamic Study

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT Using a real‐world psoriasis cohort, we established the pharmacokinetic‐pharmacodynamic (PKPD) relationship for the biologic therapy adalimumab and evaluated the clinical utility and cost‐effectiveness of a proactive therapeutic drug monitoring (TDM) strategy.
Shan Pan, Teresa Tsakok, Ruoheng Wei, Nick Dand, Floris C. Loeff, Karien Bloem, Annick de Vries, David Baudry, Michael Duckworth, Angela Pushpa‐Rajah, Alice Russell, Ali Alsharqi, Gabrielle Becher, Ruth Murphy, Shyamal Wahie, Andrew Wright, Christopher E. M. Griffiths, Nick J. Reynolds, Jonathan Barker, Richard B. Warren, A. David Burden, Theo Rispens, Satveer K. Mahil, Joseph F. Standing, Catherine H. Smith, on behalf of the BADBIR Study Group, the BSTOP Study Group and the PSORT Consortium, Marilyn Benham, Sagair Hussain, Brian Kirby, Linda Lawson, Kathleen McElhone, Anthony Ormerod, Caroline Owen, Michael R. Barnes, Paola Di Meglio, Richard Emsley, Andrea Evans, Katherine Payne   +38 more
wiley   +1 more source

Predicting Pharmacokinetic Variability and Drug Interaction Risk Using Omics‐Based Biomarkers

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT Interindividual variability in drug pharmacokinetics and susceptibility to drug–drug interactions remain major barriers in precision dosing, particularly for narrow therapeutic index drugs. While genetic factors contribute, much variability arises from dynamic influences such as physiology, disease, age, diet, microbiome, and concomitant ...
Bhagwat Prasad
wiley   +1 more source

The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects [PDF]

, 2017

core   +1 more source

Assessing physician and patient acceptance of infliximab biosimilars in rheumatoid arthritis, ankylosing spondyloarthritis and psoriatic arthritis across Germany

Patient Preference and Adherence, 2017
John Waller,1 Emma Sullivan,1 James Piercy,1 Christopher M Black,2 Sumesh Kachroo2 1Adelphi Real World, Manchester, UK; 2Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc., Kenilworth, NJ, USA Objectives: We examined ...
Waller J, Sullivan E, Piercy J, Black CM, Kachroo S   +4 more
doaj  

Perceptions and clinical use of biosimilars among rheumatologists in ArLAR countries: a cross-sectional survey. [PDF]

Front Med (Lausanne)
Adnan A, Awadh NI, Humadi YA, Gorial FI, Ziade N, Younis AA, Hmamouchi I, El Kibbi L, Halabi H, Haouichat C, Masri BK, Omer EOH, Shimal AA, Al-Obaidi AD, Jassim NA.   +14 more
europepmc   +1 more source

Nomenclature and Traceability Debate for Biosimilars: Small-Molecule Surrogates Lend Support for Distinguishable Nonproprietary Names [PDF]

, 2015

core   +1 more source

Biosimilars in Adult and Pediatric Noninfectious Uveitis. [PDF]

Clin Ophthalmol
Ploeger CG, Carvalho Soares Valentim C, Guner ME, Kabaalioglu Guner M.   +3 more
europepmc   +1 more source

Sandoz Inc. v. Amgen Inc.: Removing Barriers to Market Access for Biosimilar Manufacturers [PDF]

, 2019
Koya, Moyosore O.
core   +1 more source

The economic pressures for biosimilar drug use in cancer medicine [PDF]

, 2012
Paul Cornes
core   +1 more source